Response of cell growth and retinoic acid receptor expression to retinoic acid in neoplastic and non-neoplastic prostate cell lines

Prostate

Volumn 30, Issue 3, 1997, Pages 174-182

  Jones, Helen E ^a   Eaton, Colby L ^a   Barrow, Denise ^a   Dutkowski, Carol ^a   Griffiths, Keith ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

DU 145; PC 3; prostate cancer; RA; RARs

Indexed keywords

RETINOIC ACID; RETINOID X RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; DOG; DRUG EFFECT; GROWTH REGULATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN SYNTHESIS REGULATION; RECEPTOR DENSITY; RECEPTOR UPREGULATION;

ADENOCARCINOMA; ANIMALS; BLOTTING, NORTHERN; CELL LINE; DNA PROBES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TIME FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0030969733     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970215)30:3<174::AID-PROS5>3.0.CO;2-M     Document Type: Article

References (61)

1. Sporn MB, Roberts AB, Goodman DS: "The Retinoids," Vol 1-2. New York: Academic Press, 1984.
2. De Luca LM: Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J 5:2924-2933, 1991.
3. Sporn MB, Dunlop NM, Newton DL, Smith JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogues (retinoids). Fed Proc 35:1332-1338, 1976.
4. Lippmann SM, Kessler JF, Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents. 1. Cancer Treat Rep 71:391-405, 1987.
5. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaur P, Degos L: All trans retinoic acid as a differentiation therapy for acute promyelocytic leukaemia. 1. Clinical results. Blood 76:1704-1709, 1990.
6. Hong WK, Lippmann SM, Itri LM, Karp D, Lee JS, Byers R, Schantz SP, Kramer AM. Lotan R, Peters LJ, Dimery IW, Brown WB, Goepfert H: Prevention of second primary tumours with isotretinoin in squamous cell carcinoma of the head and neck. New Engl J Med 323:795-801, 1990.
7. Lippmann SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff LH, Gutterman JU, Hong WK: 13-cis retinoic acid and interferon α-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235-241, 1992.
8. Boccardo F, Canobbio L, Resasco M, Decensi AU, Pastorino G, Brema F: Phase II study of tamoxifen and high dose retinyl acetate in patients with advanced breast cancer. J Cancer Res Clin Oncol 116:503-506, 1990.
9. Leid M, Kastner P, Chambon P: Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem 17:427-433, 1992.
10. Giguere V, Ong ES, Segui P, Evans RM: Identification of a receptor for the morphogen retinoic acid. Nature 330:624-629, 1987.
11. Brand N, Petkovich M, Krust A, Chambon P, de The H, Marchio A, Tiollois P, Dejean A: Identification of a second human retinoic acid receptor. Nature 332:850-853, 1988.
12. Krust A, Kastner P, Petkovich M, Zelent A, Chambon P: A third human retinoic acid receptor h RARγ. Proc Natl Acad Sci USA 86:5310-5314, 1989.
13. Zelent A, Krust A, Petkovich M, Kastner P, Chambon P: Cloning of murine α and β receptors and a novel receptor γ predominately expressed in skin. Nature 339:714-717, 1989.
14. Kastner P, Krust A, Mendelsohn C, Garnier JM, Zelent A, Leroy P, Staub A, Chambon P: Murine isoforms of retinoic acid receptor γ with specific patterns of expression. Proc Natl Acad Sci USA 87:2700-2704, 1990.
15. Leroy P, Krust A, Zelent A, Mendelsohn C, Garnier JM, Kastner P, Dierich A, Chambon P: Multiple isoforms of the mouse retinoic acid receptor a are generated by alternative splicing and differential induction by retinoic acid. EMBO J 10:59-69, 1991.
16. Zelent A, Mendelsohn C, Kastner P, Krust A, Garnier GM, Ruffenach F, Leroy P, Chambon P: Differentially expressed isoforms of the mouse retinoic acid receptor β are generated by the usage of two promoters and alternative splicing. EMBO J 10:71-81, 1991.
17. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM: Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 345:224-229, 1990.
18. Mangelsdorf DJ, Borgmeyer U, Heyman RA, Zhou JY, Ong ES, Oro AE, Kakizuka A, Evans RM: Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 6:329-344, 1992.
19. Umesono K, Giguere V, Glass CK, Rosenfeld MG, Evans RM: Retinoic acid and thyroid hormone induce gene expression through a common response element. Nature 336:262-265, 1988.
20. Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, Chen JY, Staub A, Garnier JM, Mader S, Chambon P: Purification, cloning and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 68:377-395, 1992.
21. Giguere V: Retinoic acid receptors and cellular retinoid-binding proteins: complex interplay in retinoid signalling. Endocrine Rev 15:61-79, 1994.
22. de The H, Vivanco-Ruiz M, Tiollais P, Stunnenburg H, Dejean A: Identification of a retinoic acid response element in the retinoic acid receptor β gene. Nature 343: 177-180, 1990.
23. Sucov HM, Murakami KK, Evans RM: Characterization of an autoregulated response element in the mouse retinoic acid receptor type β gene. Proc Natl Acad Sci USA 87:5392-5396, 1990.
24. Schroder EW, Block PH: Retinoids: tumour preventers or tumour enhancers? J Natl Cancer Inst 65:671-674, 1980.
25. Chaproniere DM, Webber MM: Dexamethasone and retinyl acetate similiarly inhibit and stimulate EGF-or insulin-induced proliferation of prostatic epithelium. J Cell Physiol 122:249-253, 1985.
26. Peehl DM, Wong ST, Stamey TA: Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate 23:69-78, 1993.
27. Fong C-J, Sutkowski DM, Braun EJ, Bauer KD, Sherwood ER, Lee C, Kozlowski JM: Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J Urol 149:1190-1194, 1993.
28. Dahiya R, Boyle B, Park HD, Kurhanewicz J, MacDonald JM, Narayan P: 13-cis-retinoic acid-mediated growth inhibition of DU-145 human prostate cancer cells. Biochem Mol Biol Int 32:1-12, 1994.
29. Dahiya R, Park HD, Cusick J, Vessella RL, Fournier G, Narayan P: Inhibition of tumourigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 59:126-132, 1994.
30. Takeda N, Yamaoto A: Simultaneous determination of 13-cis- and all-trans-retinoic acid and retinol in human serum by high-performance liquid chromatography. J Chromatogr 657:53-59, 1994.
31. Meyer E, Lambert WE, De Leenheer AP: Simultaneous determination of endogenous retinoic acid isomers and retinol in human plasma by isocratic normal-phase HPLC with ultraviolet detection. Clin Chem 40:48-57, 1994.
32. Rottman JN, Widom RL, Nadal-Ginard B, Mahdavi V, Karathanasis SK: A retinoic acid-responsive element in the apolipoprotein Al gene distinguishes between two different retinoic acid response pathways. Mol Cell Biol 11:3814-3820, 1991.
33. Leav I, Cavazos LF: Some morphologic features of normal and pathologic canine prostate. In Goland M (ed): "Normal and Abnormal Growth of the Prostate." Springfield, IL: Charles C. Thomas, 1975, pp 69-101.
34. Kaighn M, Narayan K, Ohnuki Y, Lechner J, Jones L: Establishment and characterization of a human prostatic carcinoma cell line. Invest Urol 17:16-23, 1979.
35. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU145). Int J Cancer 21:274-281, 1978.
36. Eaton CL, Pierrepoint CG: Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: Isolation and characterization of a neoplastic prostatic epithelial cell line CPA 1. Prostate 12:129-143, 1988.
37. Eaton CL, Pierrepoint CG: Epithelial and fibroblastoid cell lines derived from the normal canine prostate. 1. Separation and characterization of epithelial and stromal components. Prostate 3:277-290, 1982.
38. Chirgwin JM, Przybyia AE, MacDonald RJ, Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonucleases. Biochem 18:5294-5299, 1979.
39. Lord E: The use of range in place of the standard deviation in the t test. Biometrika 34:141-167, 1947.
40. Jones HE, Eaton CL, Barrow D, Dutkowski C, Griffiths K: Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor alpha in neoplastic and non-neoplastic prostatic cell lines. Prostate (in press).
41. Harant H, Korschineck I, Krupitza G, Fazeny B, Dittrich C, Grunt TW: Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. Br J Cancer 68:530-536, 1993.
42. Van der Leede BM, van der Brink CE, van der Saag PT: Retinoic acid receptor and retinoid X receptor expression in retinoic acid resistant human tumour cell lines. Mol Carcinogenesis 8:112-122, 1993.
43. Moasser MM, De Blasio A, Dmitrovsky E: Response and resistance to retinoic acid are mediated through the retinoic acid nuclear receptor γ in human teratocarcinomas. Oncogene 9:833-840, 1994.
44. Zou CP, Clifford JL, Xu XC, Sacks PG, Chambon P, Hong WK, Lotan R: Modulation by retinoic acid (RA) of squamous cell differentiation, cellular RA-binding proteins and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines. Cancer Res 54:5479-5487, 1994.
45. Igawa M, Tanabe T, Chodak GW, Rukstalis DB: N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC-3 cells. Prostate 24:299-305, 1994.
46. Pollard M, Luckert PH, Sporn MB: Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide. Cancer Res 51:3610-3611, 1991.
47. Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC: Dietary fenretinide, a synthetic retinoid, decreases the tumour incidence and the tumour mass of ras and myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 53:4461-4465, 1993.
48. Gebert GF, Moghal N, Frangioni JV, Sugarbaker DJ, Neal BG: High frequency of retinoic acid receptor β abnormalities in human lung cancer. Oncogene 6:1859-1868, 1991.
49. de The H, Chomienne C, Lanotte M, Degos L, Dejean A: The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 347:558-561, 1990.
50. Clifford JL, Petkovich M, Chambon P, Lotan R: Modulation by retinoids of mRNA levels for nuclear retinoic acid receptors in murine melanoma cells. Mol Endocrinol 4:1546-1555, 1990.
51. Nervi C, Vollberg TM, Grippo JF, Lucas DA, George MD, Sherman MI, Shudo K, Jetten AM: Expression of nuclear retinoic acid receptors in wild type and mutant embryonal carcinoma PCC4 AZA 1R cells. Cell Growth Diff 1:535-542, 1990.
52. Griffiths K, Adlercreutz H, Boyle P, Denis L, Nicholson RI, Morton MS (eds): Carcinoma of the prostate. In "Nutrition and Cancer," ISIS Oxford pp 99-112, 1996.
53. Burgess AW: Epidermal growth factor and transforming growth factor alpha. Br Med Bull 45:401-424, 1989.
54. Graham S, Haughey B, Marshall J, Priore R, Byers T, Rzepka T, Mettlin C, Pontes JE: Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst 70:687-692, 1983.
55. Heshmat MY, Kaul L, Kovi J, Jackson MA, Jackson AF, Jones GW, Edson M, Enterline JP, Worrell RG, Perry SL: Nutrition and prostate cancer: a case control study. Prostate 67:7-17, 1985.
56. Kolonel LN, Hankin JH, Yoshizawa CN: Vitamin A and prostate cancer in elderly men: enhancement of risk. Cancer Res 47:2982-2985, 1987.
57. Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB, Schroeder FH: A case-control study of prostatic cancer with reference to dietary habits. Prostate 12:179-190, 1988.
58. Reichman ME, Hayes RB, Ziegler RG, Schatzkin A, Taylor PR, Kahle LL, Fraumeni JF: Serum vitamin A and subsequent development of prostate cancer in the first National Health and Nutrition Examination Survey epidemiologic follow-up study. Cancer Res 50:2311-2315, 1990.
59. Wakeling AE, Newboult E, Peters SW: Effects of antioestrogen on the proliferation of MCF-7 human breast cancer cells. J Mol Endocrinol 2:225-234, 1989.
60. Jonat C, Rahmsdorf HJ, Park KK, Cafo ACB, Gebel S, Ponta H, Herrlich P: Anti-tumour promotion and antiinflammation: downregulation of AP1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62:1189-1204, 1990.
61. Philips A, Chalbos D, Rochefort H: Estradiol increases and anti-oestrogen antagonises the growth factor induced activator protein 1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268:14103-14108, 1993.